Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PERSIST

Financiado

Cerrado

Persisting Transgenesis

For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even... ver más

30/06/2013

UNISR

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

UNIVERSITA VITASALUTE SAN RAFFAELE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 28 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-06-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

28 Participantes

UNISR

0.00€ | Lider

RHUL

N.D. | Participante

EIT MANUFACTURING ASBL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2016-5324-1 Nuevas Herramientas de Ingeniería genómica para el tratamien... 304K€ Cerrado

SCRIBE RNA-based gene writing in human cells 2M€ Cerrado

CCedit Coiled coil mediated exonuclease tethering technology for th... 150K€ Cerrado

PID2020-118597RB-I00 TECNOLOGIAS AVANZADAS PARA LA INSERCION PRECISA Y EFICIENTE... 278K€ Cerrado

BROADCAST Molecular mechanisms, functions and applications of RNA-gui... 1M€ Cerrado

SynTra Controlling Gene Expression with Synthetic Cell-Penetrating... 2M€ Cerrado

Líder del proyecto

UNIVERSITA VITASALUTE SAN RAFFAELE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even caused serious adverse events leading to termination of trials. PERSIST will explore the use of highly innovative gene-modifying and delivery technologies and capitalize on recent discoveries in gene expression control to develop radical solutions to the problem of precisely controlling the fate and expression of exogenous genetic information in gene therapy with applications in these and other deadly diseases. Our proposal combines 20 of Europe’s outstanding experts from 8 countries in the field of genetic engineering for persisting gene expression. Partners have pioneered the use of Zinc Finger Nucleases, engineered recombinases and transposases for gene targeting, synthetic promoters, epigenetic switches and micro-RNA for regulating gene expression, developed state-of-the-art gene delivery platforms based on lentiviral, AAV and gutless adenoviral vectors, conducted front-line clinical trials, and productively collaborated in previous FP projects. PERSIST includes 16 work packages of which 6 focus on vector innovations (part A: emerging technologies), 6 on applications & evaluation (part B), 1 on process development and the remaining 2 on training/dissemination and project management including IPR issues. Targeting deadly diseases, such as inherited immunodeficiencies, storage disorders and haemophilias, PERSIST is in line with the Strategic Research Agenda (SRA) of the Innovative Medicines Initiative (IMI) and will result in: faster discovery and development of better medicines; more attractive professional environment for scientists; better European expertise and know-how to attract biomedical R&D investment in Europe; and a stronger competitive advantage for SMEs, spin-offs and start-ups to enhance Europe’s economy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores